Research programme: urea intravitreal - Innovations In Sight

Drug Profile

Research programme: urea intravitreal - Innovations In Sight

Alternative Names: Glaucoma therapy - Innovations In Sight; Glaucoma therapy - VitreoRetinal; Neurosolve

Latest Information Update: 20 Sep 2011

Price : $50

At a glance

  • Originator VitreoRetinal Technologies
  • Developer Innovations In Sight
  • Class Skin disorder therapies; Urea compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Glaucoma

Most Recent Events

  • 20 Sep 2011 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top